These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26218766)

  • 1. Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes.
    Carruthers M; Cathcart P; Feneley MR
    Aging Male; 2015; 18(4):217-27. PubMed ID: 26218766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone supplementation: what and how to give.
    Jockenhövel F
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.
    Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
    Med J Aust; 2016 Sep; 205(5):228-31. PubMed ID: 27581270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H; Gooren LJ
    Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-Onset Hypogonadism and Testosterone Replacement in Older Men.
    Bhattacharya RK; Bhattacharya SB
    Clin Geriatr Med; 2015 Nov; 31(4):631-44. PubMed ID: 26476121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome.
    Rodriguez-Tolrà J; Torremadé J; di Gregorio S; Del Rio L; Franco E
    Andrology; 2013 Jul; 1(4):570-5. PubMed ID: 23686863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.
    Leichtnam ML; Rolland H; Wüthrich P; Guy RH
    Pharm Res; 2006 Jun; 23(6):1117-32. PubMed ID: 16755346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy in male late onset hypogonadism: available pharmacological strategies.
    Turchi P; Simi S; Pescatori ES
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):61-8. PubMed ID: 16760628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of testosterone on cardiovascular disease: a critical review of the literature.
    Su JJ; Park SK; Hsieh TM
    Am J Mens Health; 2014 Nov; 8(6):470-91. PubMed ID: 24563500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of testosterone replacement therapy.
    Hameed A; Brothwood T; Bouloux P
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1213-9. PubMed ID: 14649214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Testosterone substitution in patients with hypogonadism].
    Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
    Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
    Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
    Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.